Skip Navigation


Journal of the National Cancer Institute Advance Access originally published online on January 8, 2008
JNCI Journal of the National Cancer Institute 2008 100(2):155; doi:10.1093/jnci/djm261
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
100/2/155    most recent
djm261v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Khamaisi, M.
Right arrow Articles by Elad, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Khamaisi, M.
Right arrow Articles by Elad, S.
Related Collections
Right arrowRelated Article in JNCI
Right arrowResponse to this Correspondence
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press.

CORRESPONDENCE

Re: Intravenous Bisphosphonate Therapy and Inflammatory Conditions or Surgery of the Jaw: A Population-Based Analysis

Mogher Khamaisi

Sharon Elad

Affiliations of authors: Departments of Medicine (MK) and Oral Medicine (SE) and Diabetes Center (MK), Hadassah Hospital and Hebrew University Medical School, Jerusalem, Israel

Correspondence to: Mogher Khamaisi, MD, PhD, Department of Medicine, Hadassah Hospital, PO Box 12000, Jerusalem 91240, Israel (e-mail: murir@hadassah.org.il).

The first 10% of the full text of this article appears below.

Wilkinson et al. (1) recently reported in the Journal that users of intravenous bisphosphonates had an increased risk of inflammatory conditions, osteomyelitis, and surgical procedures of the jaw and facial bones. The inflammatory condition investigated in this paper was bisphosphonate-related osteonecrosis of the jaws, which was first described in 2003 (2).

A negative . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Article in JNCI

HPV-Positive Head and Neck Cancer Patients Fare Better than HPV-Negative Patients
Liz Savage and Andrea Widener
J Natl Cancer Inst 2008 100: 227. [Extract] [Full Text] [PDF]

Response to this Correspondence

Response: Re: Intravenous Bisphosphonate Therapy and Inflammatory Conditions or Surgery of the Jaw: A Population-Based Analysis
Gregg S. Wilkinson, Yong-Fang Kuo, Jean L. Freeman, and James S. Goodwin
J Natl Cancer Inst 2008 100: 155-156. [Extract] [Full Text] [PDF]